Opening Doors in TB Drug Discovery

  • Author: Scott Williams
  • Published Date: 02 February 2013
  • Source / Publisher: ChemMedChem/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
thumbnail image: Opening Doors in TB Drug Discovery

Related Societies

GlaxoSmithKline (GSK), Tres Cantos Medicines Development Campus (TCMDC), Madrid, Spain, is building on an open-innovation strategy. They began with the publication of their antimalarial compound set and now they have screened their entire pharmaceutical library of more than two million compounds to find any compound that can inhibit tuberculosis (TB).

Lluís Ballell and colleagues describe the structure, anti-tubercular properties, and drug-like profile of 177 promising "hits" that will be made available to researchers. Ballell's team envisages that the release of such anti-TB screening sets will enable the creation of a virtual community of scientists engaged in drug discovery efforts toward addressing neglected diseases.

Article Views: 2595

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from, please contact us first for permission and consult our permission guidance prior to making your request

Follow on Facebook Follow on Twitter Follow on YouTube Follow on LinkedIn Follow on Instagram RSS Sign up for newsletters

Magazine of Chemistry Europe (16 European Chemical Societies) published by Wiley-VCH